-
公开(公告)号：US10245310B2
公开(公告)日：2019-04-02
申请号：US15501474
申请日：2015-08-05
发明人： Francesco Berti , Roberta Cozzi , Domenico Maione , Cira Daniela Rinaudo , Immaculada Margarit Y Ros , Guido Grandi
IPC分类号： A61K39/09 , A61K39/095 , A61K47/48
摘要： The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 are Streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.
-
公开(公告)号：US10086060B2
公开(公告)日：2018-10-02
申请号：US15630679
申请日：2017-06-22
摘要： The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).
-
公开(公告)号：US20180009852A1
公开(公告)日：2018-01-11
申请号：US15698434
申请日：2017-09-07
IPC分类号： C07K14/245 , A61K39/095 , C12N9/10 , C07K14/22 , A61K39/00 , A61K39/108
CPC分类号： C07K14/245 , A61K39/00 , A61K39/0258 , A61K39/095 , C07K14/22 , C12N9/1051 , Y02A50/474
摘要： Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
-
公开(公告)号：US09249198B2
公开(公告)日：2016-02-02
申请号：US14450082
申请日：2014-08-01
发明人： Claire Fraser , Cesira Galeotti , Guido Grandi , Erin Hickey , Vega Masignani , Marirosa Mora , Jeremy Petersen , Mariagrazia Pizza , Rino Rappuoli , Giulio Ratti , Vincenzo Scarlato , Maria Scarselli , Herve Tettelin , J. Craig Venter
CPC分类号： C07K14/22 , A61K38/00 , A61K39/00 , A61K39/095 , A61K2039/55505 , Y10S530/806 , Y10S530/825
摘要： The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
-
公开(公告)号：US10336794B2
公开(公告)日：2019-07-02
申请号：US15698434
申请日：2017-09-07
IPC分类号： A61K39/02 , C07K14/22 , C07K14/245 , A61K39/095 , C12N9/10 , A61K39/108 , A61K39/00
摘要： Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
-
公开(公告)号：US10195263B2
公开(公告)日：2019-02-05
申请号：US15589834
申请日：2017-05-08
发明人： Fabio Bagnoli , Massimiliano Biagini , Luigi Fiaschi , Guido Grandi , Ravi Pratap Narayan Mishra , Nathalie Norais , Maria Scarselli
IPC分类号： A61K39/085 , C07K14/31 , A61K39/00
摘要： An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
-
公开(公告)号：US20180104324A1
公开(公告)日：2018-04-19
申请号：US15819312
申请日：2017-11-21
IPC分类号： A61K39/09 , A61K39/13 , A61K9/00 , A61K39/00 , A61K39/05 , A61K39/08 , A61K39/02 , C12N7/00 , A61K39/12
CPC分类号： A61K39/092 , A61K9/0019 , A61K39/0018 , A61K39/05 , A61K39/08 , A61K39/099 , A61K39/12 , A61K39/13 , A61K47/646 , A61K2039/55 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , C12N7/00 , C12N2770/32334 , C12N2770/32634 , Y02A50/466
摘要： Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to carrier proteins.
-
公开(公告)号：US09926344B2
公开(公告)日：2018-03-27
申请号：US14420831
申请日：2013-08-29
发明人： Fabio Bagnoli , Fabiana Falugi , Guido Grandi , Massimo Mariani , Mikkel Nissum , Michele Pallaoro , Silvana Savino
IPC分类号： C07K14/31 , A61K39/085 , A61K39/00
CPC分类号： C07K14/31 , A61K39/085 , A61K2039/55505
摘要： Elimination of disulphide bond formation of cysteine-containing S. aureus antigens enhances antigen stability. The invention provides variant forms of cysteine-containing S. aureus antigen with a point mutation that replaces, deletes or modifies the cysteine residue.
-
公开(公告)号：US09764027B2
公开(公告)日：2017-09-19
申请号：US14424839
申请日：2013-09-18
CPC分类号： A61K39/39 , A61K39/092 , A61K39/095 , A61K2039/55555
摘要： The present invention provides an outer membrane vesicle (OMV) from a Gram-negative bacterium, comprising at least one heterologous protein that is free in the lumen of the OMV, wherein the OMV is capable of eliciting an immune response to the heterologous protein when administered to a mammal. The invention also provides methods for preparing the OMVs of the invention, pharmaceutical compositions comprising the OMVs of the invention, especially immunogenic compositions and vaccines, and methods of generating an antibody immune response in a mammal using OMVs.
-
公开(公告)号：US09642904B2
公开(公告)日：2017-05-09
申请号：US14961772
申请日：2015-12-07
发明人： Fabio Bagnoli , Massimiliano Biagini , Luigi Fiaschi , Guido Grandi , Ravi Pratap Narayan Mishra , Nathalie Norais , Maria Scarselli
IPC分类号： A61K39/085 , C07K14/31 , A61K39/00
CPC分类号： A61K39/085 , A61K39/00 , C07K14/31 , C07K2319/00
摘要： An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.079 秒)